Literature DB >> 20038760

The mechanism of action of glatiramer acetate treatment in multiple sclerosis.

Michael K Racke1, Amy E Lovett-Racke, Nitin J Karandikar.   

Abstract

OBJECTIVE: Glatiramer acetate (formerly known as copolymer 1) is the major noninterferon immunomodulatory agent used in the treatment of relapsing-remitting multiple sclerosis. Its mechanism of action over the past 40 years has evolved with our understanding of the immune response.
METHODS: We review the various mechanisms that have been proposed for this random polymer over the years, with emphasis on recent methods that utilize modern immunologic techniques.
RESULTS: Studies describing processes such as immune deviation and effects on regulatory T cells and antigen-presenting cells are presented.
CONCLUSIONS: Effects of glatiramer acetate on the immune response have evolved as our technical abilities and knowledge of the immune response itself have developed.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20038760     DOI: 10.1212/WNL.0b013e3181c97e39

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  38 in total

1.  Chemotherapeutics in the treatment of multiple sclerosis.

Authors:  Bernd C Kieseier; Douglas R Jeffery
Journal:  Ther Adv Neurol Disord       Date:  2010-09       Impact factor: 6.570

Review 2.  Restoring the balance between disease and repair in multiple sclerosis: insights from mouse models.

Authors:  Robert H Miller; Sharyl L Fyffe-Maricich
Journal:  Dis Model Mech       Date:  2010-07-20       Impact factor: 5.758

3.  Multiple sclerosis: Five new things.

Authors:  Jacqueline A Nicholas; Aaron L Boster; Michael K Racke
Journal:  Neurol Clin Pract       Date:  2013-10

Review 4.  Treating relapsing-remitting multiple sclerosis: therapy effects on brain atrophy.

Authors:  Angela Vidal-Jordana; Jaume Sastre-Garriga; Alex Rovira; Xavier Montalban
Journal:  J Neurol       Date:  2015-06-05       Impact factor: 4.849

Review 5.  Managing MS in a changing treatment landscape.

Authors:  Martin Duddy; Aiden Haghikia; Eleonora Cocco; Christian Eggers; Jelena Drulovic; Olga Carmona; Helene Zéphir; Ralf Gold
Journal:  J Neurol       Date:  2011-03-25       Impact factor: 4.849

Review 6.  Translational research in neurology and neuroscience 2010: multiple sclerosis.

Authors:  Olaf Stüve; Bernd C Kieseier; Bernhard Hemmer; Hans-Peter Hartung; Amer Awad; Elliot M Frohman; Benjamin M Greenberg; Michael K Racke; Scott S Zamvil; J Theodore Phillips; Ralf Gold; Andrew Chan; Uwe Zettl; Ron Milo; Ellen Marder; Omar Khan; Todd N Eagar
Journal:  Arch Neurol       Date:  2010-07-12

Review 7.  Immune regulation of multiple sclerosis by CD8+ T cells.

Authors:  Sushmita Sinha; Farah R Itani; Nitin J Karandikar
Journal:  Immunol Res       Date:  2014-08       Impact factor: 2.829

Review 8.  Infection risk in patients on multiple sclerosis therapeutics.

Authors:  Eric M Williamson; Joseph R Berger
Journal:  CNS Drugs       Date:  2015-03       Impact factor: 5.749

Review 9.  Next-generation therapeutic solutions for age-related macular degeneration.

Authors:  Khrishen Cunnusamy; Rafael Ufret-Vincenty; Shusheng Wang
Journal:  Pharm Pat Anal       Date:  2012-05

10.  The role of glatiramer acetate in the early treatment of multiple sclerosis.

Authors:  David W Brandes
Journal:  Neuropsychiatr Dis Treat       Date:  2010-06-24       Impact factor: 2.570

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.